We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Faces Potential $7.1 Billion IRS Fine; Are Other Drugmakers at Risk?
Amgen Faces Potential $7.1 Billion IRS Fine; Are Other Drugmakers at Risk?
Amgen disclosed this week that the Internal Revenue Service (IRS) is seeking $7.1 billion in back taxes and fines relating to how the drugmaker split profits between its U.S. and Puerto Rican manufacturing hubs.